Italian economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes'c colon cancer

被引：0
|
作者：
Di Costanzo, F.
Sobrero, A.
Twelves, C.
Douillard, J.
Giuliani, G.
Patel, K.
Garrison, L.
Cassidy, J.
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Univ Washington, Seattle, WA 98195 USA
[3] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[4] Roche Italy, Milan, Italy
[5] Ctr Rene Gauducheau, St Herblain, France
[6] Univ Leeds, Bradford, W Yorkshire, England
[7] Bradford NHS Trust, Bradford, W Yorkshire, England
[8] Osped San Martino Genova, Genoa, Italy
[9] AO Careggi, Dept Med Oncol, Florence, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes' C colon cancer in an Italian hospital setting
    Di Costanzo, F.
    Sobrero, A.
    Twelves, C.
    Cassidy, J.
    Douillard, J.-Y.
    Giuliani, G.
    Patel, K. K.
    Garrison, L. P.
    EJC SUPPLEMENTS, 2005, 3 (02): : 192 - 192
  • [2] Capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (PTS) with Dukes' C colon cancer: Pharmacoeconomic evaluation of X-act trial data from a Czech perspective
    Jiraskova, Lucia
    Dolezal, Tomas
    ANNALS OF ONCOLOGY, 2006, 17 : 123 - 123
  • [3] Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    McKendrick, Joseph
    Cassidy, James
    Van Hazel, Guy
    Twelves, Chris
    Wong, Alfred
    Nowacki, Marek
    Kroning, Hendrik
    Cervantes, Andres
    Herrmann, Richard
    Burris, Howard, III
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 74
  • [4] Capecitabine vs. Bolus 5-FU/LV as adjuvant therapy for patients with Dukes' C colon cancer: Pharmacoeconomic evaluation of X-act trial data from Czech perspective
    Jiraskova, L.
    Dolezal, T.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [5] Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer.
    Twelves, C
    Wong, A
    Nowacki, M
    McKendrick, J
    van Hazel, G
    Douillard, JY
    Díaz-Rubio, E
    Cassidy, J
    Maroun, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [6] Post-study treatment does not influence outcome in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    Borner, M.
    Cassidy, J.
    Cervantes, A.
    Koralewski, P.
    Zaluski, J.
    Schuller, J.
    Husseini, F.
    Teller, S.
    Twelves, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 179 - 179
  • [7] Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer:: the X-ACT trial
    Cassidy, J
    Douillard, Y
    Twelves, C
    McKendrick, JJ
    Scheithauer, W
    Bustová, I
    Johnston, PG
    Lesniewski-Kmak, L
    Jelic, S
    Fountzilas, G
    Coxon, F
    Díaz-Rubio, E
    Maughan, TS
    Malzyner, A
    Bertetto, O
    Beham, A
    Figer, A
    Dufour, P
    Patel, KK
    Cowell, W
    Garrison, LP
    BRITISH JOURNAL OF CANCER, 2006, 94 (08) : 1122 - 1129
  • [8] Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
    J Cassidy
    J-Y Douillard
    C Twelves
    J J McKendrick
    W Scheithauer
    I Bustová
    P G Johnston
    K Lesniewski-Kmak
    S Jelic
    G Fountzilas
    F Coxon
    E Díaz-Rubio
    T S Maughan
    A Malzyner
    O Bertetto
    A Beham
    A Figer
    P Dufour
    K K Patel
    W Cowell
    L P Garrison
    British Journal of Cancer, 2006, 94 : 1122 - 1129
  • [9] Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
    Diaz-Rubio, E
    Burris, H
    Douillard, JY
    Coxon, FY
    Maughan, T
    Bertetto, O
    Schueller, J
    Husseini, F
    Marschner, N
    Scheithauer, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [10] Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes' C colon cancer: No differences in treatment arms that could influence survival outcome.
    Cassidy, J
    Koralewski, P
    Husseini, F
    Twelves, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 267S - 267S
12345